Lexicon Pharmaceuticals, Inc. (LXRX) Makes Progress in Product Pipeline Development

Lexicon Pharmaceuticals (NASDAQ:LXRX) is one of the fastest-growing penny stocks to buy now. On November 18 at the Jefferies London Healthcare Conference 2025, Lexicon Pharmaceuticals (NASDAQ:LXRX) reiterated it is making significant progress in developing its pipeline.

For starters, it is preparing for the end-of-phase two meeting with the US Food and Drug Administration for pilavapadin, a candidate drug targeting neuropathic pain. Additionally, it is accelerating patient enrollment in the SONATA trial for hypertrophic cardiomyopathy (HCM). Lexicon is also resubmitting Zynquista for type 1 diabetes to the FDA in early 2026.

On November 10, at the American Heart Association Annual Scientific Sessions 2025, Lexicon delivered topline results for sotagliflozin, showing significant improvements in heart failure patients with preserved ejection fraction.

“Although sotagliflozin was approved more than two years ago for heart failure patients with or without diabetes, our study is the first to demonstrate important clinical benefits for patients with preserved ejection fraction without diabetes,” said Dr. Juan J Badimon at Mount Sinai Medical Center.

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) is a biopharmaceutical company that discovers, develops, and commercializes medicines for serious and chronic diseases. The company focuses on cardiometabolic (heart and metabolic health) and neuroscience (nervous system) conditions.

While we acknowledge the potential of LXRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: Top 10 Stocks Offering High Upside Potential in Data Centers and 10 Best Breakout Stocks to Invest In.

Disclosure: None. This article is originally published at Insider Monkey.